Erin O'Brien

The drug has shown statistically significant, clinically meaningful reductions in symptoms of depression, anhedonia.

Trial results underscore the importance of early diagnosis and treatment in patients with Alzheimer disease.

Announcement follows the FDA’s accelerated approval and unanimous endorsement of the drug earlier this year.

Researchers focused on elements across several categories, including brain state, cumulative exposure, and treatment and individualized parameters.

Although more than 90% of children had at least 1 caregiver-reported sleep problem, only 20% had a clinician-documented sleep problem.

The advisory identifies positive and negative effects of social media usage and next steps for making social media safer for youth.

Study investigates connections between rTMS and factors including depression and cognitive performance.

The risperidone formulation is the first FDA-approved treatment for this patient population to use technology enabling controlled release over time.

Treatment is now the first and only once-at-bedtime oxybate to be approved by the FDA for individuals with narcolepsy.

If approved, the drug will be the first FDA-approved treatment for agitation associated with Alzheimer dementia in the United States.

Public responses to mass shootings, in particular, often include speculations about the shooter’s mental state. But what is the real connection between gun violence and mental illness?

The AMA, substance abuse experts share their thoughts on this decision and what it means for psychiatric clinicians and their patients.

Study results show that the therapy activates serotonin (5-HT) and improves stress-coping ability.

Results show that the novel formulation of dexmethylphenidate can be taken either with or without food.

Leaders from across the United States aim to work together to develop bipartisan solutions for the youth mental health crisis.

The agency’s conclusions are based on regulatory oversight needed to manage risks associated with CBD and other cannabis-derived products.

The ongoing study demonstrated statistically significant improvements over baseline in comparison to results at 6 weeks.

What's the latest in dementia?

The novel atypical antipsychotic is already FDA-approved for the treatment of schizophrenia in adults.

Check out the best clinical pearls from the 2022 Neuroscience Education Institute (NEI) Congress!

The investigators suggested that future research explore the connection between ADHD risk in children and depression in pregnant parents.

This latest submission completes the FDA filing that was initiated in May.

The drug is in development for the treatment of acute depressive disorders and depression with suicidality.

Policies include opposition to government involvement in medical practice and support of access to abortion care.

Results show comparisons between intranasal and intracerebroventricular distribution of an oxytocin derivative.

Experts share the benefits of motivational interviewing when working with this patient population—and how clinicians can incorporate it into their practice.

An expert discusses key differences and some ways to avoid missing the appropriate diagnosis in these patient populations.

Connections between autism risk, sleep disturbances, insomnia risk genes and circadian pathways were analyzed.

The American Academy of Psychiatry and the Law scholarship aims to foster a welcoming and supportive environment for forensic psychiatrists of color.

The underlying neural mechanisms identified may help clinicians better understand ketamine response in human patients.